TY - JOUR
T1 - Predictive variables of sustained virological response after early discontinuation of triple therapy with telaprevir for genotype-1 HCV infection
AU - Acero Fernández, Doroteo
AU - Morillas Cunill, Rosa
AU - Ferri Iglesias, María José
AU - Torras Collell, Xavier
AU - Vergara Gómez, Mercedes
AU - Zaragoza Velasco, Natividad
AU - López Nuñez, Carmen
AU - Forné Bardera, Montserrat
AU - Delgado Gómez, Mercedes
AU - Barenys Lacha, Mercè
AU - Torres Salinas, Miquel
AU - Villar Fernández, Margarita
AU - Durández Lázaro, Rosa
AU - Mariño Mendez, Zoe
PY - 2016/6/1
Y1 - 2016/6/1
N2 - © 2015 Elsevier España, S.L.U. y AEEH y AEG Background Pivotal phase studies of telaprevir (TLV) and boceprevir (BOV) showed 10–56% rates of early treatment interruption. However, there have been no reports on the sustained virological response (SVR) rates of these patients. Aim To assess the SVR rate in a large cohort of patients who discontinued triple therapy with TLV or BOV for reasons other than stopping rules and to identify variables predicting SVR. Material and method A survey was sent to 15 hospitals in Catalonia asking them to report all TLV/BOV treatments finished by 31 May 2014. Demographic, clinical, laboratory, liver fibrosis and therapeutic data were recorded for treatments with early discontinuation. Logistic regression analysis, ROC curves and prognostic assessment of the variables identified were calculated. Results Twelve hospitals responded to the survey, representing 467 treatments and 121 (21.2%) early discontinuations, 76 (62.8%) due to stopping rules and 45 (37.2%) for other reasons. Early discontinuation was more frequent with BOV [38.2% (50/131) versus 21.1% (71/336) p < 0.005], mainly due to stopping rules [78% (39/50) versus 52.1% (37/71); p = 0.004]. SVR was achieved in 21/121 patients (17.4%), 19/71 (26.8%) treated with TLV and 2/50 (4.0%) treated with BOV. In patients discontinuing treatment for reasons other than stopping rules, SVR was achieved in 19/37 (55.9%) treated with TLV and in 2/11 (18.2%) treated with BOV. The SVR rate in patients treated with TLV who discontinued due to a severe adverse event was 61.5% (16/26). A logistic regression analysis was performed only with triple therapy with TLV and early discontinuation. The predictive variables of SVR were undetectable HCV-RNA at treatment week 4 and treatment length longer than 11 weeks. Treatment duration longer than 11 weeks showed the best accuracy (0.794), with a positive predictive value of 0.928. Conclusions Early discontinuation of TLV-based triple therapy due to reasons other than stopping rules still have a significant SVR rate (55.9%). Undetectable HVC-RNA at week 4 of treatment and treatment duration longer than 11 weeks are predictive of SVR in this subset of patients.
AB - © 2015 Elsevier España, S.L.U. y AEEH y AEG Background Pivotal phase studies of telaprevir (TLV) and boceprevir (BOV) showed 10–56% rates of early treatment interruption. However, there have been no reports on the sustained virological response (SVR) rates of these patients. Aim To assess the SVR rate in a large cohort of patients who discontinued triple therapy with TLV or BOV for reasons other than stopping rules and to identify variables predicting SVR. Material and method A survey was sent to 15 hospitals in Catalonia asking them to report all TLV/BOV treatments finished by 31 May 2014. Demographic, clinical, laboratory, liver fibrosis and therapeutic data were recorded for treatments with early discontinuation. Logistic regression analysis, ROC curves and prognostic assessment of the variables identified were calculated. Results Twelve hospitals responded to the survey, representing 467 treatments and 121 (21.2%) early discontinuations, 76 (62.8%) due to stopping rules and 45 (37.2%) for other reasons. Early discontinuation was more frequent with BOV [38.2% (50/131) versus 21.1% (71/336) p < 0.005], mainly due to stopping rules [78% (39/50) versus 52.1% (37/71); p = 0.004]. SVR was achieved in 21/121 patients (17.4%), 19/71 (26.8%) treated with TLV and 2/50 (4.0%) treated with BOV. In patients discontinuing treatment for reasons other than stopping rules, SVR was achieved in 19/37 (55.9%) treated with TLV and in 2/11 (18.2%) treated with BOV. The SVR rate in patients treated with TLV who discontinued due to a severe adverse event was 61.5% (16/26). A logistic regression analysis was performed only with triple therapy with TLV and early discontinuation. The predictive variables of SVR were undetectable HCV-RNA at treatment week 4 and treatment length longer than 11 weeks. Treatment duration longer than 11 weeks showed the best accuracy (0.794), with a positive predictive value of 0.928. Conclusions Early discontinuation of TLV-based triple therapy due to reasons other than stopping rules still have a significant SVR rate (55.9%). Undetectable HVC-RNA at week 4 of treatment and treatment duration longer than 11 weeks are predictive of SVR in this subset of patients.
KW - Boceprevir
KW - Chronic hepatitis C
KW - Early discontinuation
KW - Sustained virological response
KW - Telaprevir
U2 - 10.1016/j.gastrohep.2015.10.005
DO - 10.1016/j.gastrohep.2015.10.005
M3 - Article
VL - 39
SP - 377
EP - 384
JO - Gastroenterologia y Hepatologia
JF - Gastroenterologia y Hepatologia
SN - 0210-5705
IS - 6
ER -